PHILADELPHIA and REHOVOT, Israel, May 9, 2011 /PRNewswire/ —
Rosetta Genomics (NASDAQ:
ROSG) today announced that the United States Patent and
Trademark Office (USPTO) has issued U.S. Patent No. 7,943,745,
which is related to human hsa-miR-497 and its variants and covers
the composition of matter.
Human hsa-miR-497 is an important component of the Company’s
miRview™ mets and mets2 diagnostic tests for the accurate
identification of the tissue of origin in Cancers of Unknown
Primary (CUP) and difficult to diagnose metastatic cancer cases.
Rosetta Genomics recently announced the launch of an oncology sales
team for these advanced microRNA-based diagnostic tests in the
“We remain focused on building an exceptionally strong
intellectual property portfolio that allows us to support and
protect our products and processes. This is particularly important
as we recently launched our first company-led commercialization
efforts in the U.S., and this patent provides a further barrier to
entry for would-be competitors,” commented Kenneth A. Berlin,
President and Chief Executive Officer. “As pioneers in the microRNA
field, we believe that Rosetta has the broadest and deepest
intellectual property portfolio for microRNA-based
Worldwide, Rosetta Genomics has been issued 21 patents and has
filed more than 105 patent applications, 5 of which have been
allowed, to protect its commercial diagnostic products. Many of
these applications protect the specific microRNAs used in the
company’s products and cover composition of matter, diagnostic
applications, therapeutic applications and discovery process
applications for microRNAs in humans.
About miRview™ ProductsmiRview™ are a series of
microRNA-based diagnostic products offered by Rosetta Genomics.
miRview™ mets and miRview™ mets2 accurately identify